Helena T. D. S.
- Country
- Portugal
- Department
- PT10006: Serviço de Gastroenterologia - Exames Especiais
Research Overview
- Phase 3 Randomized Double-Blind Placebo-Controlled Study of Tulisokibart Efficacy and Safety in Moderately to Severely Active Crohn's Disease
- Efficacy and Safety of Risankizumab as Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety of Risankizumab in Maintenance and Long-term Extension for Moderately to Severely Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 211 of 298 partner sites.
Specializations
Inflammatory Bowel Disease Research
The investigator specializes in advanced therapeutic approaches for inflammatory bowel diseases, with particular focus on combination therapy studies for both ulcerative colitis and Crohn's disease.
- Moderate to Severe Ulcerative Colitis Management
- Crohn's Disease Treatment Innovation
- Combination Therapy Assessment
Explores novel therapeutic combinations using targeted immunomodulators for gastrointestinal inflammatory conditions.
Immunotherapy Applications
Conducts research in targeted immunotherapy approaches, specifically investigating the therapeutic potential of monoclonal antibodies in inflammatory conditions.
- Biologic Therapy Optimization
- Dual-mechanism Treatment Strategies
- Long-term Efficacy Assessment
Evaluates innovative therapeutic combinations to enhance treatment outcomes in inflammatory disorders.
Clinical Therapeutics
Focuses on developing advanced treatment protocols for patients with moderate to severe inflammatory conditions requiring enhanced therapeutic interventions.
- Treatment Response Assessment
- Therapeutic Strategy Development
- Patient Outcome Optimization
Investigates comparative effectiveness of monotherapy versus combination approaches in inflammatory diseases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.